This study is for children and young adults, ages 3 to 21, with specific types of brain cancer, like glioblastoma or newly found DIPG (diffuse intrinsic pontine glioma). The trial is testing a drug called indoximod, which helps boost the immune system by blocking the IDO pathway. The IDO pathway is something that can stop our immune system from fighting off cancer. By adding indoximod to regular treatments like chemotherapy and radiation, researchers hope to slow down tumor growth.

Key Points:

• This trial is for children who have specific brain cancers and no prior treatments for newly diagnosed DIPG.
• Participants need to be able to swallow pills and must have certain health conditions met, like good liver and kidney function.
• The study can enroll up to 140 participants, and it's important to check eligibility, like any past treatments or infections.

Pregnant women and those who cannot swallow pills are not eligible. The trial uses special criteria called iRANO to measure how well the treatment works. If you're interested, your doctor can help determine if you meet the criteria to join this trial.